Skip to content
Find a Provider
Craig A. Mullen, M.D., Ph.D.

Craig A. Mullen, M.D., Ph.D.

Hematology & Oncology , Pediatrics , Pediatric Brain and Spinal Cord Tumor , Cancer

5 out of 5 stars
40 Ratings
2 Comments
UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Not Accepting New Patients

Contact

Office (585) 275-2981
Fax (585) 273-1039

About Me

Acute Lymphoblastic Leukemia
Bone Marrow Transplantation
Childhood Cancer
Infections in Immunocompromised Hosts
Biological Therapies of Cancer
Use of Computer Technology To Improve Drug Compliance
Acute Lymphoblastic Leukemia
Bone Marrow Transplantation
Childhood Cancer
Infections in Immunocompromised Hosts
Biological Therapies of Cancer
Use of Computer Technology To Improve Drug Compliance

Certified Specialties

Pediatric Hematology-Oncology - American Board of Pediatrics

Faculty Appointments

Professor Emeritus - Department of Pediatrics, Hematology and Oncology (SMD)

Professor (Part-Time) - Department of Medicine, Hematology/Oncology (SMD) - Joint

Credentials

Residency & Fellowship

Fellowship, Research, National Institutes of Health, NIH. 1992 - 1994

Fellowship, Pediatric Hematology-Oncology, National Institutes of Health, NIH. 1989 - 1992

Residency, Pediatrics, Children's Medical Center of Dallas. 1987 - 1989

Internship, Pediatrics, Children's Medical Center of Dallas. 1986 - 1987

Education

MD | University of Chicago Pritzker School of Medicine. 1986

PHD | University of Chicago. 1984

Awards

Award for Second International Symposium on Minor Histocompatibility Antigens. 2002

Dean's Excellence Award. 1999

American Association of Cancer Research. 1992

Alpha Omega Alpha. 1986

Dr. Harold Lamport Biomedical Research Award (for the best PhD dissertation in biomedical research). 1986

Phi Beta Kappa. 1978

Research

Dr. Mullen current research work examines the bone marrow microenvironment of acute lymphoblastic leukemia. The current goal of the work is to identify the molecular mechanisms by which nonmalignant cells in the marrow microenvironment that provide antiapoptotic support for leukemia cells. Ultimat...
Dr. Mullen current research work examines the bone marrow microenvironment of acute lymphoblastic leukemia. The current goal of the work is to identify the molecular mechanisms by which nonmalignant cells in the marrow microenvironment that provide antiapoptotic support for leukemia cells. Ultimately this may identify new "drug-able" targets that may improve leukemia therapy.

Publications

Journal Articles

Gene Expression and Survival of Acute Lymphoblastic Leukemia Cells After Allogeneic Transplant.

Schenone D, Andolina JR, Rademacher B, Fountaine TJ, Edwards E, Nunez L, Qiu M, Sharma S, Mullen CA

Anticancer research.. 2021 June 41 (6):2781-2793. Epub 1900 01 01.

A case of a rapidly-changing skin lesion in an 11-year-old male

Kwiatkowski V; Franco AI; Cordisco MR;Mullen CA.

Pediatrics In Review. 2021; .

Support of acute lymphoblastic leukemia cells by nonmalignant bone marrow stromal cells.

Usmani S, Sivagnanalingam U, Tkachenko O, Nunez L, Shand JC, Mullen CA

Oncology letters.. 2019 June 17 (6):5039-5049. Epub 03/22/2019.

Successful reduced-intensity conditioning hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria with aplastic anemia in two children.

Andolina JR, Reinish AL, Akhtar R, Noronha S, Shand JC, Girvin A, Korones DN, Bruckner LB, Mullen CA, Curran KJ, Boulad F

Pediatric blood & cancer.. 2018 August 65 (8):e27218. Epub 05/03/2018.

Acute chest syndrome in sickle cell disease: Effect of genotype and asthma

Pahl, K.; Mullen, C.A.

Experimental Biology and Medicine. 2016; 241(7): 745-748.

Patterns of diagnosis and misdiagnosis in pediatric cancer and relationship to survival

Chen, J.; Mullen, C.A.

Journal of Pediatric Hematology and Oncology. 2016; 39: e110-e115.

ManageMyCondition: A Standard Framework for the Development of Cloud-based Medical Condition Management Applications

Tapparello, C; Heinzelman, W; Conn, K; Mullen, CA.

IEEE Xplore: IEEE International Workshop on Cloud Connected Health. 2016; .

Developing Medical Condition Management Applications Using Manage My Condition

Tapparello, C; Heinzelman, W; Conn, K; Mullen, CA.

IEEE Xplore: IEEE International Conference on Connected Health: Applications, Systems and Engineering Technologies. 2016; .

Acute lymphoid leukemia cells with greater stem cell antigen-1 (Ly6a/Sca-1) expression exhibit higher levels of metalloproteinase activity and are more aggressive in vivo.

Hsu YC, Mildenstein K, Hunter K, Tkachenko O, Mullen CA

PloS one.. 2014 9 (2):e88966. Epub 02/20/2014.

Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease.

Oyeku SO, Driscoll MC, Cohen HW, Trachtman R, Pashankar F, Mullen C, Giardina PJ, Velazco N, Racine AD, Green NS

Pediatric blood & cancer.. 2013 April 60 (4):653-8. Epub 11/05/2012.

Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea.

Green NS, Ender KL, Pashankar F, Driscoll C, Giardina PJ, Mullen CA, Clark LN, Manwani D, Crotty J, Kisselev S, Neville KA, Hoppe C, Barral S

PloS one.. 2013 8 (2):e55709. Epub 02/07/2013.

''Good Enough'' Medicine: Noninferiority clinical trials and the management of fever and neutropenia

Mullen, C.A.

Pediatric Blood and Cancer. 2012; 59(3): 415-416.

Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease.

Milner LA, Becker MW, Bernstein SH, Bruckner L, Friedberg JW, Holland GA, Ifthikharuddin JJ, Liesveld JL, Mathes EJ, Menchel HL, Mullen CA, Sasson T, Phillips GL

American journal of hematology.. 2011 August 86 (8):712-4. Epub 05/31/2011.

Acute lymphoblastic leukemia cells that survive combination chemotherapy in vivo remain sensitive to allogeneic immune effects.

Jansson J, Hsu YC, Kuzin II, Campbell A, Mullen CA

Leukemia research.. 2011 June 35 (6):800-7. Epub 11/12/2010.

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.. 2011 February 1552 (4):e56-93. Epub 1900 01 01.

Evidence of B cell immune responses to acute lymphoblastic leukemia in murine allogeneic hematopoietic stem cell transplantation recipients treated with donor lymphocyte infusion and/or vaccination.

Mullen CA, Campbell A, Tkachenko O, Jansson J, Hsu YC

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2011 February 17 (2):226-38. Epub 09/08/2010.

Differential gene expression in acute lymphoblastic leukemia cells surviving allogeneic transplant.

Shand JC, Jansson J, Hsu YC, Campbell A, Mullen CA

Cancer immunology, immunotherapy : CII.. 2010 November 59 (11):1633-44. Epub 07/03/2010.

Risk factors for umbilical venous catheter-associated thrombosis in very low birth weight infants.

Narang S, Roy J, Stevens TP, Butler-O'Hara M, Mullen CA, D'Angio CT

Pediatric blood & cancer.. 2009 January 52 (1):75-9. Epub 1900 01 01.

High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells.

Young FM, Campbell A, Emo KL, Jansson J, Wang PY, Jordan CT, Mullen CA

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2008 June 14 (6):622-30. Epub 04/14/2008.

Medical and non-medical barriers to outpatient treatment of fever and neutropenia in children with cancer.

Quezada G, Sunderland T, Chan KW, Rolston K, Mullen CA

Pediatric blood & cancer.. 2007 March 48 (3):273-7. Epub 1900 01 01.

Hematopoietic stem cell recipients do not develop post-transplantation immune tolerance to antigens present on minimal residual disease.

Natzke AM, Shaw JL, McKeller MR, Emo KL, Mullen CA

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2007 January 13 (1):34-45. Epub 1900 01 01.

Interferon-alpha after autologous stem cell transplantation in pediatric patients with advanced Hodgkin's lymphoma.

Petropoulos D, Worth LL, Mullen CA, Lockhart S, Choroszy M, Chan KW

Bone marrow transplantation.. 2006 September 38 (5):345-9. Epub 1900 01 01.

Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies.

Petropoulos D, Worth LL, Mullen CA, Madden R, Mahajan A, Choroszy M, Ha CS, Champlin RC, Chan KW

Bone marrow transplantation.. 2006 March 37 (5):463-7. Epub 1900 01 01.

Bacterial infections in low-risk, febrile neutropenic patients.

Kamana M, Escalante C, Mullen CA, Frisbee-Hume S, Rolston KV

Cancer.. 2005 July 15104 (2):422-6. Epub 1900 01 01.

Augmentation of post transplant immunity: antigen encounter at the time of hematopoietic stem cell transplantation enhances antigen-specific donor T-cell responses in the post transplant repertoire.

Mori S, Kocak U, Shaw JL, Mullen CA

Bone marrow transplantation.. 2005 April 35 (8):793-801. Epub 1900 01 01.

Cellular tumor vaccines administered after T cell-depleted allogeneic bone marrow transplantation induce effective anti-tumor immune responses.

Mundhada S, Shaw J, Mori S, Savary CA, Mullen CA

Leukemia & lymphoma.. 2005 April 46 (4):571-80. Epub 1900 01 01.

Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.

Tran H, Petropoulos D, Worth L, Mullen CA, Madden T, Andersson B, Choroszy M, Nguyen J, Webb SK, Chan KW

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2004 November 10 (11):805-12. Epub 1900 01 01.

Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients.

Mullen CA

The Pediatric infectious disease journal.. 2003 December 22 (12):1138-42. Epub 1900 01 01.

Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome.

Gordon N, Mullen CA, Tran H, Worth L, Gomez Almaguer D, Chan KW

Journal of pediatric hematology/oncology.. 2003 October 25 (10):824-6. Epub 1900 01 01.

Non-albicans Candida is the most common cause of candidemia in pediatric cancer patients.

Mullen CA, Abd El-Baki H, Samir H, Tarrand JJ, Rolston KV

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.. 2003 May 11 (5):321-5. Epub 03/11/2003.

Analysis of immunodominance among minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation.

Mori S, El-Baki H, Mullen CA

Bone marrow transplantation.. 2003 May 31 (10):865-75. Epub 1900 01 01.

Treatment of leukemia relapse with recombinant granulocyte-macrophage colony stimulating factor (rhGM-CSF) following unrelated umbilical cord blood transplant: Induction of graft-vs.-leukemia.

Worth LL, Mullen CA, Choroszy M, Koontz S, Chan K

Pediatric transplantation.. 2002 October 6 (5):439-42. Epub 1900 01 01.

Suicide gene therapy using E. coli beta-galactosidase.

Farquhar D, Pan BF, Sakurai M, Ghosh A, Mullen CA, Nelson JA

Cancer chemotherapy and pharmacology.. 2002 July 50 (1):65-70. Epub 06/08/2002.

Lorazepam for seizure prophylaxis during high-dose busulfan administration.

Chan KW, Mullen CA, Worth LL, Choroszy M, Koontz S, Tran H, Slopis J

Bone marrow transplantation.. 2002 June 29 (12):963-5. Epub 1900 01 01.

Influence of tumor vaccines on graft versus tumor activity and graft versus host disease in allogeneic bone marrow transplantation.

Mullen CA

Leukemia & lymphoma.. 2002 March 43 (3):503-10. Epub 1900 01 01.

Down-regulation of antihost alloreactivity after bone marrow transplant permits relapse of hematological malignancy.

Wang J, Shaw JL, Mullen CA

Cancer research.. 2002 January 162 (1):208-12. Epub 1900 01 01.

Fever and neutropenia in children with solid tumors is similar in severity and outcome to that in children with leukemia.

Koçak U, Rolston KV, Mullen CA

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.. 2002 January 10 (1):58-64. Epub 1900 01 01.

Clinical parameters associated with low bacteremia risk in 1100 pediatric oncology patients with fever and neutropenia.

Baorto EP, Aquino VM, Mullen CA, Buchanan GR, DeBaun MR

Cancer.. 2001 August 1592 (4):909-13. Epub 1900 01 01.

Bone marrow transplant conditioning intensified with liposomal clodronate to eliminate residual host antigen presenting cells fails to ameliorate GVHD and increases PERI-BMT mortality.

Everse LA, Anderson LD, van Rooijen N, Mullen CA

Transplantation.. 2001 March 1571 (5):611-8. Epub 1900 01 01.

Which children with fever and neutropenia can be safely treated as outpatients?

Mullen CA

British journal of haematology.. 2001 March 112 (4):832-7. Epub 1900 01 01.

Ethical considerations in allogeneic hematopoietic cell transplantation for children with slowly fatal conditions.

Mullen CA, Chan KW

Bone marrow transplantation.. 2000 November 26 (9):1030-1. Epub 1900 01 01.

Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.

Anderson LD, Mori S, Mann S, Savary CA, Mullen CA

Cancer research.. 2000 October 1560 (20):5797-802. Epub 1900 01 01.

Unrelated umbilical cord blood transplantation in infancy for mucopolysaccharidosis type IIB (Hunter syndrome) complicated by autoimmune hemolytic anemia.

Mullen CA, Thompson JN, Richard LA, Chan KW

Bone marrow transplantation.. 2000 May 25 (10):1093-7. Epub 1900 01 01.

Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease.

Anderson LD, Savary CA, Mullen CA

Blood.. 2000 April 195 (7):2426-33. Epub 1900 01 01.

Use of a herpes thymidine kinase/neomycin phosphotransferase chimeric gene for metabolic suicide gene transfer.

Candotti F, Agbaria R, Mullen CA, Touraine R, Balzarini J, Johns DG, Blaese RM

Cancer gene therapy.. 2000 April 7 (4):574-80. Epub 1900 01 01.

Fever and neutropenia in pediatric hematopoietic stem cell transplant patients.

Mullen CA, Nair J, Sandesh S, Chan KW

Bone marrow transplantation.. 2000 January 25 (1):59-65. Epub 1900 01 01.

Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.

Worth L, Tran H, Petropoulos D, Culbert S, Mullen C, Roberts W, Przepiorka D, Chan K

Bone marrow transplantation.. 1999 November 24 (9):947-52. Epub 1900 01 01.

Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients.

Mullen CA, Petropoulos D, Roberts WM, Rytting M, Zipf T, Chan KW, Culbert SJ, Danielson M, Jeha SS, Kuttesch JF, Rolston KV

Cancer.. 1999 July 186 (1):126-34. Epub 1900 01 01.

Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation.

Przepiorka D, Petropoulos D, Mullen CA, Danielson M, Mattewada V, Chan KW

Bone marrow transplantation.. 1999 June 23 (12):1291-5. Epub 1900 01 01.

Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice.

Kuriyama S, Kikukawa M, Masui K, Okuda H, Nakatani T, Sakamoto T, Yoshiji H, Fukui H, Ikenaka K, Mullen CA, Tsujii T

International journal of cancer.. 1999 May 1781 (4):592-7. Epub 1900 01 01.

Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine.

Anderson LD, Petropoulos D, Everse LA, Mullen CA

Cancer research.. 1999 April 159 (7):1525-30. Epub 1900 01 01.

Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant Rev.

Ragheb JA, Couture L, Mullen C, Ridgway A, Morgan RA

Human gene therapy.. 1999 January 110 (1):103-12. Epub 1900 01 01.

Economic and resource utilization analysis of outpatient management of fever and neutropenia in low-risk pediatric patients with cancer.

Mullen CA, Petropoulos D, Roberts WM, Rytting M, Zipf T, Chan KW, Culbert SJ, Danielson M, Jeha SS, Kuttesch JF, Rolston KV

Journal of pediatric hematology/oncology.. 1999 21 (3):212-8. Epub 1900 01 01.

Ganciclovir chemoablation of herpes thymidine kinase suicide gene-modified tumors produces tumor necrosis and induces systemic immune responses.

Mullen CA, Anderson L, Woods K, Nishino M, Petropoulos D

Human gene therapy.. 1998 September 209 (14):2019-30. Epub 1900 01 01.

Allogeneic peripheral blood stem cell transplantation for active hemophagocytic lymphohistiocytosis.

Chan KW, Mullen CA, Korbling M

Bone marrow transplantation.. 1998 August 22 (3):301-2. Epub 1900 01 01.

Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults.

Walker RE, Carter CS, Muul L, Natarajan V, Herpin BR, Leitman SF, Klein HG, Mullen CA, Metcalf JA, Baseler M, Falloon J, Davey RT, Kovacs JA, Polis MA, Masur H, Blaese RM, Lane HC

Nature medicine.. 1998 July 4 (7):852-6. Epub 1900 01 01.

Acute reversible arthropathy in a pediatric patient with cancer treated with a short course of ciprofloxacin for febrile neutropenia.

Mullen CA, Petropoulos D, Rytting M, Jeha S, Zipf T, Roberts WM, Rolston KV

Journal of pediatric hematology/oncology.. 1998 20 (5):516-7. Epub 1900 01 01.

Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil.

Kuriyama S, Masui K, Sakamoto T, Nakatani T, Kikukawa M, Tsujinoue H, Mitoro A, Yamazaki M, Yoshiji H, Fukui H, Ikenaka K, Mullen CA, Tsujii T

Anticancer research.. 1998 18 (5A):3399-406. Epub 1900 01 01.

Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment.

Ishii-Morita H, Agbaria R, Mullen CA, Hirano H, Koeplin DA, Ram Z, Oldfield EH, Johns DG, Blaese RM

Gene therapy.. 1997 March 4 (3):244-51. Epub 1900 01 01.

Autologous lymphoblastoid cell lines stably transfected with Plasmodium falciparum circumsporozoite protein as targets in cytotoxic T-lymphocyte assays.

Kumar A, Kang YH, Gowda K, Mullen CA, Gordon DM, Kumar S, Hoffman SL

Immunology letters.. 1997 March 55 (3):183-7. Epub 1900 01 01.

Glycinamide ribonucleotide transformylase undergoes pH-dependent dimerization.

Mullen CA, Jennings PA

Journal of molecular biology.. 1996 October 11262 (5):746-55. Epub 1900 01 01.

Molecular analysis of T lymphocyte-directed gene therapy for adenosine deaminase deficiency: long-term expression in vivo of genes introduced with a retroviral vector.

Mullen CA, Snitzer K, Culver KW, Morgan RA, Anderson WF, Blaese RM

Human gene therapy.. 1996 June 107 (9):1123-9. Epub 1900 01 01.

Treatment of microscopic pulmonary metastases with recombinant autologous tumor vaccine expressing interleukin 6 and Escherichia coli cytosine deaminase suicide genes.

Mullen CA, Petropoulos D, Lowe RM

Cancer research.. 1996 March 1556 (6):1361-6. Epub 1900 01 01.

Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene.

Khil MS, Kim JH, Mullen CA, Kim SH, Freytag SO

Clinical cancer research : an official journal of the American Association for Cancer Research.. 1996 January 2 (1):53-7. Epub 1900 01 01.

T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.

Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA, Anderson WF

Science.. 1995 October 20270 (5235):475-80. Epub 1900 01 01.

Retrovirus mediated gene transfer as therapy for adenosine deaminase (ADA) deficiency.

Ramsey WJ, Mullen CA, Blaese RM

Leukemia.. 1995 October 9 Suppl 1 :S70. Epub 1900 01 01.

Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency.

Kohn DB, Weinberg KI, Nolta JA, Heiss LN, Lenarsky C, Crooks GM, Hanley ME, Annett G, Brooks JS, el-Khoureiy A

Nature medicine.. 1995 October 1 (10):1017-23. Epub 1900 01 01.

5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory.

Consalvo M, Mullen CA, Modesti A, Musiani P, Allione A, Cavallo F, Giovarelli M, Forni G

The Journal of immunology : official journal of the American Association of Immunologists.. 1995 May 15154 (10):5302-12. Epub 1900 01 01.

Bacterial cytosine deaminase suicide gene transduction renders hepatocellular carcinoma sensitive to the prodrug 5-fluorocytosine

Kuriyama S, Masui K, Sakamoto T, Nakatani T, Tominaga K, Fukui H, Ikenaka K, Mullen CA, Tsujii T.

International Hepatology Communications. 1995; 4: 72-79.

A multiinstitutional survey of the Wiskott-Aldrich syndrome.

Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA

The Journal of pediatrics.. 1994 December 125 (6 Pt 1):876-85. Epub 1900 01 01.

Metabolic suicide genes in gene therapy.

Mullen CA

Pharmacology & therapeutics.. 1994 August 63 (2):199-207. Epub 1900 01 01.

Retroviral vectors containing chimeric promoter/enhancer elements exhibit cell-type-specific gene expression.

Couture LA, Mullen CA, Morgan RA

Human gene therapy.. 1994 June 5 (6):667-77. Epub 1900 01 01.

Effects of IMP dehydrogenase inhibitors on the phosphorylation of ganciclovir in MOLT-4 cells before and after herpes simplex virus thymidine kinase gene transduction.

Agbaria R, Mullen CA, Hartman NR, Cooney DA, Hao Z, Blaese RM, Johns DG

Molecular pharmacology.. 1994 April 45 (4):777-82. Epub 1900 01 01.

Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor.

Mullen CA, Coale MM, Lowe R, Blaese RM

Cancer research.. 1994 March 1554 (6):1503-6. Epub 1900 01 01.

Splenectomy and/or bone marrow transplantation in the management of the Wiskott-Aldrich syndrome: long-term follow-up of 62 cases.

Mullen CA, Anderson KD, Blaese RM

Blood.. 1993 November 1582 (10):2961-6. Epub 1900 01 01.

A study of the safety and survival of the adoptive transfer of genetically marked syngeneic lymphocytes in HIV-infected identical twins.

Walker R, Blaese RM, Carter CS, Chang L, Klein H, Lane HC, Leitman SF, Mullen CA, Larson M

Human gene therapy.. 1993 October 4 (5):659-80. Epub 1900 01 01.

Strategies for gene therapy.

Blaese RM, Mullen CA, Ramsey WJ

Pathologie-biologie.. 1993 October 41 (8):672-6. Epub 1900 01 01.

Fibrosarcoma cells transduced with the IL-6 gene exhibited reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential.

Mullen CA, Coale MM, Levy AT, Stetler-Stevenson WG, Liotta LA, Brandt S, Blaese RM

Cancer research.. 1992 November 152 (21):6020-4. Epub 1900 01 01.

Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system.

Mullen CA, Kilstrup M, Blaese RM

Proceedings of the National Academy of Sciences of the United States of America.. 1992 January 189 (1):33-7. Epub 1900 01 01.

Early hospital discharge of children with cancer treated for fever and neutropenia: identification and management of the low-risk patient.

Mullen CA, Buchanan GR

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 1990 December 8 (12):1998-2004. Epub 1900 01 01.

Highly immunogenic regressor tumor cells can prevent development of postsurgical tumor immunity.

Mullen CA, Rowley DA, Schreiber H

Cellular immunology.. 1989 March 119 (1):101-13. Epub 1900 01 01.

Immunoregulation by natural killer cells.

Abruzzo LV, Mullen CA, Rowley DA

Cellular immunology.. 1986 April 198 (2):266-78. Epub 1900 01 01.

Multiple cancers. Tumor burden permits the outgrowth of other cancers.

Mullen CA, Urban JL, Van Waes C, Rowley DA, Schreiber H

The Journal of experimental medicine.. 1985 November 1162 (5):1665-82. Epub 1900 01 01.

Tumor growth and evasion of immune destruction: UV-induced tumors as a model.

Mullen CA, Schreiber H

Survey of immunologic research. 1985 4 (4):264-70. Epub 1900 01 01.

Books

Pediatric Oncology (2005)

Chapter: Supportive Care in Pediatric Oncology: Part I

Authors: Rodriguez N, Madden RM, Mullen CA

Publisher: Springer, New York, NY 2005

Pediatric Oncology (2005)

Chapter: Supportive Care in Pediatric Oncology: Part II

Authors: Madden RM, Koontz-Webb S, Zhukovsky DS, Mullen CA

Publisher: Springer, New York, NY 2005

Gene Therapy of Cancer (1998)

Chapter: Cytosine deaminase as a suicide gene in cancer gene therapy

Authors: Mullen CA

Publisher: Academic Press, San Diego, CA 1998

Encyclopedia of Cancer (1997)

Chapter: Gene Therapy of Cancer

Authors: Mullen CA

Publisher: Academic Press, San Diego, CA 1997

Cancer Chemotherapy and Biological Response Modifiers (1996)

Chapter: Gene therapy of cancer

Authors: Mullen CA, Blaese RM

Publisher: Elsevier, Amsterdam, Neatherlands 1996

Cytokines in Cancer Therapy (1994)

Chapter: Development of live tumor vaccines using retroviral vectors for transfer of suicide genes and cytokines

Authors: Mullen CA

Publisher: Karger, Freiburg, Germany 1994

Cytokine-Induced Tumor Immunogenicity (1994)

Chapter: Herpes thymidine kinase suicide gene transfer: A review of preclinical models and proposals to treat brain tumors

Authors: Mullen CA

Publisher: Academic Press, San Diego, CA 1994

Klinische Pharmakologie (1993)

Chapter: Progress in gene therapy for immunodeficiency and cancer

Authors: Blaese RM, Mullen CA, Culver KW

Publisher: Frontiers in Biomedical Research, Munich, Germany 1993

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.

Ratings

During this visit, did this provider spend enough time with you?

5.0 stars

During this visit, did this provider show respect for what you had to say?

5.0 stars

During this visit did this provider give you easy to understand information about these health questions or concerns?

5.0 stars

During this visit, did this provider listen carefully to you?

5.0 stars

During this visit, did this provider explain things in a way that was easy to understand?

5.0 stars

Patient Comments

Excellent communications!

Jul 21, 2024

5.0 stars

Dr Mullen was calm and respectful.

Apr 07, 2024